1 Central laboratory, Cancer Hospital of China Medical University, Shenyang, China.
2 Department of Immunology, China Medical University, Shenyang, China.
Technol Cancer Res Treat. 2019 Jan 1;18:1533033818821421. doi: 10.1177/1533033818821421.
Currently, despite the advances in individualized treatment, breast cancer still remains the deadliest form of cancer in women. Diagnostic, prognostic, and therapy-predictive methods are mainly based on the evaluation of tumor tissue samples and are aimed to improve the overall therapeutic level. Therefore, the exploration of a series of circulating biomarkers, which serve as the information source of tumors and could be obtained by peripheral blood samples, represents a high field of interest. Apart from classical biomarkers, exosomes, which are nanovesicles, are emerging as an accessible and efficient source of cell information. The purpose of this review is to summarize the peculiarities of the presently available breast cancer exosomal biomarkers; the review also provides the prediction of a multitude of potential target genes of exosomal microRNAs using 4 databases.
目前，尽管个体化治疗取得了进展，但乳腺癌仍然是女性最致命的癌症形式。诊断、预后和治疗预测方法主要基于肿瘤组织样本的评估，旨在提高整体治疗水平。因此，探索一系列循环生物标志物作为肿瘤的信息源，并可通过外周血样获得，代表了一个高度关注的领域。除了经典的生物标志物外，外泌体作为纳米囊泡也正在成为获取细胞信息的一种可行且有效的来源。本综述的目的是总结目前可用的乳腺癌外泌体生物标志物的特点；该综述还使用 4 个数据库预测了大量外泌体 microRNA 的潜在靶基因。
